Literature DB >> 30859657

Searching for calcium antagonists for hypertension disease therapy from Moutan Cortex, using bioactivity integrated UHPLC-QTOF-MS.

Yujie Lu1, Yanfang Deng1, Wenjuan Liu1, Min Jiang1, Gang Bai1.   

Abstract

INTRODUCTION: Calcium channel blockers (CCBs) are currently the most commonly used drugs for the treatment of hypertension. Moutan Cortex (MC), a traditional Chinese herb, has been found to have an anti-hypertensive effect. However, its potential mechanisms in the regulation of intracellular calcium concentration ([Ca2+ ]i ) remain poorly understood.
OBJECTIVE: The main objective of this work was to identify the potential calcium antagonists from MC and study their molecular mechanisms.
METHODS: Ultra-high performance liquid chromatography-quadrupole-time-of-fight-mass spectrometry (UHPLC-QTOF-MS) analysis combined with a dual-luciferase reporter assay was utilised to systematically screen the calcium antagonistic active ingredients in the methanol extract of MC. Additionally, the molecular mechanism of these compounds was further studied using live-cell imaging analysis with the calcium ion (Ca2+ ) probe dye fluo-4/AM to monitor changes in [Ca2+ ]i .
RESULTS: Three monoterpenoids (paeoniflorin, benzoylpaeoniflorin and mudanpioside C), one phenolic acid (paeonol) and one gallotannin (1,2,3,4,6-O-pentagalloylglucose) were screened out as potential calcium antagonists in MC. Among them, the calcium antagonistic activity of benzoylpaeoniflorin, mudanpioside C and 1,2,3,4,6-O-pentagalloylglucose is first reported. Additionally, paeoniflorin, benzoylpaeoniflorin, mudanpioside C and paeonol can effectively block voltage-operated Ca2+ channels (VOCCs) to exert calcium antagonism, while 1,2,3,4,6-O-pentagalloylglucose plays a role in blocking inositol 1,4,5-trisphosphate receptors (IP3Rs).
CONCLUSION: This work indicated that the anti-hypertensive efficacy of MC acted through multiple components selectively antagonising multiple cell signalling pathways to regulate [Ca2+ ]i . Furthermore, they could be considered as a reference standard for controlling the quality of Chinese medicinal materials.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Moutan Cortex; bioactivity-integrated UHPLC-QTOF; calcium antagonists; inositol 1,4,5-trisphosphate receptors; voltage-operated Ca2+ channels

Mesh:

Substances:

Year:  2019        PMID: 30859657     DOI: 10.1002/pca.2828

Source DB:  PubMed          Journal:  Phytochem Anal        ISSN: 0958-0344            Impact factor:   3.373


  4 in total

1.  Biomechanical Restoration Potential of Pentagalloyl Glucose after Arterial Extracellular Matrix Degeneration.

Authors:  Sourav S Patnaik; Senol Piskin; Narasimha Rao Pillalamarri; Gabriela Romero; G Patricia Escobar; Eugene Sprague; Ender A Finol
Journal:  Bioengineering (Basel)       Date:  2019-07-03

2.  Zi Shen Huo Luo Formula Enhances the Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors on Hypertensive Left Ventricular Hypertrophy by Interfering With Aldosterone Breakthrough and Affecting Caveolin-1/Mineralocorticoid Receptor Colocalization and Downstream Extracellular Signal-Regulated Kinase Signaling.

Authors:  Xiaotong Song; Yue Zhao; Shijun Wang; Yuan Wang; Qian Chen; Haijun Zhao; Hua Wang; Sheng Tian; Huayun Yu; Zhichun Wu
Journal:  Front Pharmacol       Date:  2020-04-03       Impact factor: 5.810

3.  Identification of Chemical Markers for the Discrimination of Radix Angelica sinensis Grown in Geoherb and Non-Geoherb Regions Using UHPLC-QTOF-MS/MS Based Metabolomics.

Authors:  Kaixue Zhang; Menglin Yan; Shu Han; Longfei Cong; Liyao Wang; Liu Zhang; Lili Sun; Haiying Bai; Guanhua Wei; Hong Du; Min Jiang; Gang Bai; Zhigang Yang
Journal:  Molecules       Date:  2019-09-30       Impact factor: 4.411

4.  Paeoniflorin alleviates NG-nitro-L-arginine methyl ester (L-NAME)-induced gestational hypertension and upregulates silent information regulator 2 related enzyme 1 (SIRT1) to reduce H2O2-induced endothelial cell damage.

Authors:  Jingjing Wu; Dongmei Zhang; Linlin Hu; Xiaowei Zheng; Caihong Chen
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.